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Pulmonary Metastasectomy Expert Consensus Statements  
 
1. When caring for patients with cancer and pulmonary oligometastases, pulmonary 
metastasectomy (PM) should be considered within a multidisciplinary team (MDT) and 
carefully individualized.   
 
2. In oncologically and medically appropriate non-small cell lung cancer (NSCLC) patients, 
tissue from PM should be sent for genomic/molecular analysis including PD-L1 to guide 
future therapies.  
 
3. In oncologically and medically appropriate patients, PM can be considered with a 
preference for minimally invasive surgery (MIS) due to shortened postoperative 
recovery and lessened impact on quality of life.   
 
4. If goals of R0 and pulmonary parenchymal sparing are not accomplishable via MIS but 
loan themselves to open approaches (thoracotomy/sternotomy/clam shell), open 
techniques are appropriate.   
 
5. Pneumonectomy to accomplish PM is discouraged except in carefully selected patients 
undergoing multidisciplinary management.  
6. Although absolute number of pulmonary metastases is not a direct contraindication to 
PM, candidate selection for PM is best suited to patients harboring ≤ 3 pulmonary 
metastases.   
 
7. LN sampling / dissection concomitant with PM should be considered since pulmonary 
metastasis accompanied by mediastinal LN metastasis predict poor survival.  
8. Thermal ablation or stereotactic ablative body radiotherapy (SABR) is reasonable 
therapy for patients with pulmonary oligometastases particularly for patients 
considered high-risk for resection or refuse resection.   
 
9. Outside of clinical research, isolated lung perfusion is not warranted for management of 
pulmonary metastases. 
 
10. In colorectal cancer patients, PM can be considered within a MDT construct with 
systemic therapy before or after PM.  
 
11. In renal cell carcinoma patients, PM can be considered within a MDT construct.   
 
12. In malignant melanoma patients, PM can be considered within a MDT construct.   
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13. In sarcoma patients, PM can be considered within a MDT construct.   
 
14. PM in management of primary head & neck cancer can be considered in the context of 
DFI >12 months, ability to completely resection and absence of LN metastases.   
 
15. When managing nonseminomatous germ cell tumors, PM is indicated for all residual 
lung abnormalities after platin-based chemotherapy with normalized STM suspected of 
containing teratoma.   
 
16. When managing nonseminomatous germ cell tumors, contralateral lung abnormalities ≤ 
10 mm can be observed if histology of unilateral PM demonstrates complete tumor 
necrosis.   
 
17. When managing nonseminomatous germ cell tumors, PM is indicated for select patients 
with limited number of lung abnormalities after first or second-line platin-based 
chemotherapy suspected of containing viable nonseminomatous cancer and/or 
malignant transformation of teratoma into non-germ cell cancer.   
 
18. In breast cancer patients, PM can be considered within a MDT construct.   
 
Introduction  
Pulmonary metastasectomy (PM) has long been practiced, albeit in the face of a large literature 
with low level of evidence.  Recognizing a need for some standardization, the Society of 
Thoracic Surgeons (STS) Work Force of Evidence Based Surgery formed a task force and 
subjected “pulmonary metastasectomy” to STS expert consensus development process.  The 
task force membership included thoracic surgery, medical and radiation oncology.  The 
following is the resulting expert consensus, not rising to the level of guidelines due to the 
flawed supporting literature.  
 
Pulmonary metastasectomy literature characteristics  
Since 1980, greater than 1000 publications addressed pulmonary metastasectomy, without a 
single randomized controlled trial (RCT).  The overwhelming majority is surgical series, usually 
single institution, and includes single or multiple pathologies.  The pool of patients from which 
metastasectomy patients derive is not reported, allowing no comparative survival analysis.  
Historical controls are used or metastatic disease survival is assumed to be zero, a contention 
not supported by the literature.  Yet metastasectomy is infrequently performed (1-6.5%) when 
sizable populations of cancer patients are reported. [1-3]  Thus surgical case series manifest 
inherent selection bias and do not clarify the role of metastasectomy in prolongation of survival 
or cure.  The literature is further hampered by inconsistent or absent description of other local 
or systemic therapies and variable length of follow up.  Finally, the literature fails to distinguish 
between prognostic (indolent disease which will do well with any or no treatment) or predictive 
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features (discriminate ‘likely’ vs ‘unlikely’ to benefit from a particular treatment).  PM candidate 
predictive features include uncontrolled primary malignancy, non-pulmonary metastatic sites, 
non-R0 resection and positive mediastinal lymph nodes (LNs), all of which are usually 
considered operative contraindications, furthering the selection bias of surgical series. [4,5]    
A few registry articles (8 in total) have largely defined practice.  The most influential reported 
5206 patients with multiple pathologies from the International Registry of Lung Metastases 
(IRLM) [6] without a denominator of cancer patient population from which the metastasectomy 
patients derived.   
Table 1 
General Characteristics of the PM Literature 
No RCTs 
Pervasive selection bias 
No comparative survival analysis 
Inconsistent description of accompanying local or systemic therapies 
Variable follow up length 
Fail to distinguish between prognostic or predictive characteristics  
Does not clarify the role of PM in prolongation of survival or cure 
 
Methodology  
 
The Expert Consensus Task Force on Pulmonary Metastasectomy was enlisted by the STS 
Workforce on Evidence Based Surgery in order to provide clinically-relevant guidance to 
clinicians in spite of the above-stated limitations of the PM literature.  Relevant literature was 
searched for in MEDLINE for articles published in English since 1990, using MeSH terms “lung 
neoplasms + secondary,” “metastasectomy,  “pneumonectomy,” “thoracotomy,” “thoracic 
surgery, video assisted” combined with a variety of primary neoplasm sites.  Authors were free 
to select relevant articles for inclusion at their discretion.  A systematic review was not 
performed due to the overall lack of control groups. 
 
Consensus statements were developed using a modified Delphi method.  The proposed 
statements were subject to a vote using a five-point Likert scale.  An 80% response rate 
amongst authors was required, and statements in which 75% of respondents selected “agree” 
or “strongly agree” were considered to have reached consensus.  Three statements did not 
achieve 75% agreement after the first round of voting, and after minor revisions, were included 
after a second round of voting.  The ACCF/AHA classification system used in clinical practice 
guidelines to rate the strength and level of evidence was not utilized for this paper, as the 
expert consensus process adopted by STS results in opinion statements rather than formal 
recommendations. 
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Overall conceptual framework of treatment and the role of PM  
The focus of this effort is the role of resection (or ablation) of pulmonary metastases from an 
extrathoracic primary cancer.  PM inherently involves application of a local therapy in a non-
localized disease setting.  It is important to define the clinical setting and the goals of 
treatment.  
In patients who have isolated pulmonary metastases from an extrathoracic primary cancer, PM 
assumes the primary disease site is controlled and there are no other systemic metastases.  It is 
generally accepted that it makes little sense to undertake PM if there are other sites of disease 
unaddressed.  We acknowledge that this widely held consensus is based on rationale alone (no 
data is available for PM in the face of multiple unaddressed other metastatic sites).  However, 
this represents an “unopposed rationale,” as it is hard to come up with a rationale to support 
the converse.  (There are credible variations to this concept regarding timing:  sometimes the 
sequence of PM may vary relative to achieving control of the primary site or other metastases 
[e.g., liver and pulmonary metastases from colon cancer], but the fundamental concept of only 
undertaking PM in a setting where all known sites of disease are definitively addressed is 
unchanged.)  This paper does not address the situation of a “rogue metastasis,” a site of 
metastasis that is not responding while other sites appear to be well controlled and quiescent 
(but still present).  This is an emerging topic with its own complexities and beyond the scope of 
this paper. 
 A simple physical concept of the process of metastasis is widely pervasive, involving anatomic 
and mechanical aspects of the vascular and lymphatic system as determinants of how 
metastasis occurs (hematogenous or lymphatic dissemination).  While simple and appealing, 
this concept is countered by many observations [7].  Different primary tumors exhibit a 
predilection for particular metastatic sites.   Additionally, circulating tumors cells in the 
bloodstream are commonly present, even in early stage cancer patients who never 
subsequently develop metastases.  A large body of literature demonstrates that metastasis is 
an intricate multistep process [8,9].  During this process the cancer cell is transformed into 
different phenotypes (epithelial to mesenchymal transformation and back again)[-10].  Tumor 
cells are present simultaneously in many different forms and heterogeneous subpopulations, 
and can exist for a long time in a dormant state within permissive niches.  The various steps are 
influenced by tumor-cell-intrinsic genetic and epigenetic determinants as well as a complex 
array of tumor-host-interactions (e.g. a permissive microenvironment, angiogenesis, tumor 
characteristics blocking activation of host immune response) [11,12].  In the face of this large 
body of evidence we must be careful not to adhere dogmatically to a simple physical concept of 
how metastasis occurs that is clearly an oversimplification. 
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Historically, the goal of PM has been cure.  This concept would require definitive treatment of 
all sites of disease and be measured by long-term survival without recurrence, the rate of 
disease free survival (DFS).  There is no clear definition of what time frame should be 
considered to represent “long-term” survival, and in fact, this may be different in a rapidly 
growing vs an indolent tumor.  Simple definition of the rate of achieving long-term DFS would 
be clinically useful (even without a no treatment [i.e. no PM] comparison group).  However, DFS 
can be a difficult outcome measure if one considers the possibility that repeat resection of a 
recurrence may still achieve cure.  One can argue that overall survival (OS) might approximate 
DFS and cure, but we must recognize that this is imperfect, especially when one is considering 
indolent tumors and in the context of other non-PM therapies (for which information is scarce). 
In practice, PM is never considered abstractly in isolation; it is always in the context of the 
possibility of systemic therapy, which may be an alternative, or an adjunct preceding or 
following PM.  This creates difficulty in defining the role of PM and creates variability in the 
treatment approach which may affect outcomes.   
In cancers that commonly metastasize to the lung (colorectal cancer, renal cancer, melanoma, 
germ cell tumors, breast cancer), the time of cancer diagnosis, interval between primary tumor 
resection (disease free interval, DFI), presence of other metastatic sites and type of prior 
systemic therapy impact decisions about PM.  Patients with the smallest disease burden at 
initial diagnosis, longer interval since primary therapy, best response to prior systemic 
treatment and preserved performance status might derive the greatest likelihood of benefit 
from PM.    
IS PM associated with cure?   
PM appears to provide long term survival (OS, DFS) or “cure” across multiple pathologies with 
adherence to historically accepted surgical principles, including control of the primary cancer, 
absence or less commonly, control of extrathoracic metastasis, complete resection (R0), and 
ability to tolerate the resection.  Less commonly reported criteria include LN involvement, DFI 
and number of metastases.  When these criteria are achieved, the tail or flattening of OS curves 
in contemporary reports include colorectal (OS 20-52% at 7-9 yrs)[13, 14],  renal cell carcinoma 
(OS 33% 7 yrs) [15], melanoma (OS 14% 10 yr)[16], soft tissue sarcoma (OS 11- 23% 7-11 yrs) 
[17, 18], head and neck squamous cell cancer (OS 18% 13 yrs) [19], breast cancer (OS 40% at 18 
yrs) [20] and hepatocellular carcinoma (OS 38% over 10 yrs) [21].  
Is PM associated with prolonged survival (without cure)? 
Assessment would involve overall survival of patients undergoing PM compared with a similar 
cohort not undergoing PM.  The fact that to assess this requires not just a survival rate but a 
comparable comparison group makes it difficult to acquire evidence for prolongation of 
survival.  When reported, OS is larger than DFS, implying a possible survival prolongation from 
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PM: colorectal - 9 yrs OS 52%, DFS 38%[12], 7.5 yrs OS 20% DFS 17.5%; [13] soft tissue sarcoma 
– 7 yr OS 23% DFS 8%; [16] hepatocellular carcinoma – 10 yr OS 38% DFS 30% [21].   
In the case of lung cancer, so-called oligometastatic disease is difficult to reliably distinguish 
from second primary disease unless the lesions are pathologically distinct. [22]  Absence of 
involved LNs, development of cancer within prior areas of likely pre-cancer, lack of other 
metastatic sites and interval between primary and secondary tumor diagnosis may suggest 
second primary rather than metastatic disease. [23]  Resection of true second primaries have a 
high likelihood of cure, so when in doubt, pursue resection. [24]  Small series have shown 5 
years survivals in the 40% range independent of the pathologies in patients where synchronous 
lung cancers were removed, suggesting that even with oligometastatic cancer at presentation, 
resection may be of benefit. [25]   
 
Palliation:  No data exist for PM for symptom palliation.  PM as palliation of symptoms is rare, 
since pulmonary metastases seldom cause symptoms.  It stands to reason that PM can be 
considered in symptomatic patients otherwise fit to undergo resection and that situations such 
as painful, obstructing or bleeding metastases might be candidates for removal or ablation, if 
safe to do so.  Rarely, symptoms may result from airway obstruction (often amenable to 
endobronchial palliative measures). 
 
Multidisciplinary care/ therapy: Whether, when and how to integrate PM with 
systemic therapy  
Multi-disciplinary team (MDT) management should be the hallmark of both treatment and 
patient selection.  The timing of metastasectomy vis a vis systemic therapy is complex and 
requires expert input as does the risk/benefit assessment of local therapies, including surgical 
resection vs stereotactic ablative body radiation (SABR) / stereotactic body radiation therapy 
(SBRT), vs percutaneous ablation vs systemic therapy alone.  An anecdotal literature supports 
metastasectomy for diseases prone to indolent progression such as some sarcomas, renal 
carcinoma, some melanomas, lung cancers, carcinoid tumors, colorectal carcinomas.  Surgery is 
preferred in patients who will tolerate resection for tumors such as germ cell cancers where 
residual disease may be primarily teratoma but may devolve into malignant tissue if left in situ.  
Surgery is preferred for patients with chemoradiotherapy insensitive disease such as renal cell 
carcinoma and melanoma.    The advent of targeted therapies and immunotherapy has changed 
the landscape in those latter tumor types substantially in recent years, but while responses to 
immunotherapy can be prolonged and significant, they still apply only to the minority of 
patients (major response in approximately 20%).  Responses to targeted therapies are more 
common, but of shorter duration, so PM remains a consideration.  The timing of resection as 
well as the role of neoadjuvant and/or adjuvant systemic therapy is poorly informed by the 
literature.  
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In the clinical scenario of isolated pulmonary metastases, the medical oncologist’s role is to 
estimate overall prognosis, assess the utility of systemic therapy and provide input on the 
necessity, intent and timing of resection.  Important factors to consider are status of the 
primary, recurrence free survival, natural history of the disease, pathology and genotype, and 
availability of effective systemic treatment.  An initial course of immunotherapy or targeted 
therapy may be appropriate for some diseases (melanoma, renal cell cancer), reserving 
resection as consolidation to render a patient disease free or as salvage in case of symptomatic 
resistant disease. [26]  There is growing interest in controlling metastatic sites with local 
measures, which is an active area of research. [27, 28]  Especially in cases of actionable 
molecular alterations, a large portion of patients continue systemic therapy despite 
radiographic progression, assuming an established global benefit. [29]  In these cases, focus is 
shifting to the treatment of individual metastatic sites in combination with ongoing systemic 
treatment.  However, there is generally limited value in “adjuvant” therapy – especially 
chemotherapy – for a patient rendered disease free through resection (e.g. in cases of 
colorectal cancer or sarcoma).  
 
There is no literature guidance regarding timing of PM relative to completion of systemic 
therapy or safe duration of cessation of wound healing inhibiting targeted therapy prior to 
surgery.  A common anecdotal practice is to achieve “maximal” systemic control prior to PM.  If 
serial imaging a few weeks apart shows stable response without further shrinkage and 
functional status is good, PM or ablation is performed soon thereafter.  Most tyrosine kinase 
inhibitors (TKIs) used in lung cancer have minimal effect on wound healing.  In the case of driver 
mutations, it’s undesirable to interrupt therapy.  Hence EGFR TKIs, for example, are generally 
interrupted only a day or 2 prior to surgery and resumed a day or 2 after.    
 
Consensus statements: 
1. When caring for patients with cancer and pulmonary oligometastases, pulmonary 
metastasectomy (PM) should be considered within a multidisciplinary team (MDT) and 
carefully individualized. 
 
Strongly Agree: 92%  Agree: 8%     Neutral: 0%     Disagree: 0%      Strongly Disagree: 0%    
2. In oncologically and medically appropriate non-small cell lung cancer (NSCLC) patients, 
tissue from PM should be sent for genomic/molecular analysis including PD-L1 to guide 
future therapies.  
 
Strongly Agree: 67%  Agree: 8%     Neutral: 8%     Disagree: 17%      Strongly Disagree: 0%     
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Evaluation of a patient being considered for PM 
 
Selection/exclusion of patients for PM  
In patients who have isolated pulmonary metastases from an extrathoracic primary cancer, PM 
assumes the primary disease site is controlled and there are no other systemic metastases or if 
present, are being actively managed.   
 
No evidence defines “oligometastatic” disease or adequate DFI generalizable to all metastatic 
pathologies.   
 
Imaging modalities  
Imaging of the patient considered for PM does not differ from that of a patient evaluation for 
resectability of primary lung cancer.  Number, location and technical resectability of metastases 
are best evaluated by chest CT.  Extrathoracic disease is evaluated by PET scan if the primary 
was avid (many renal cell carcinomas are not).   
 
Risk assessment  
Operative ‘risk’ is defined by hospital mortality or morbidity.   Risk assessment of the patient 
considered for PM does not differ from that of a patient evaluation for medical operability of 
primary lung cancer.  Clinical evaluation delineating dyspnea, performance status, and exercise 
capacity supported by pulmonary function testing (spirometry, diffusion capacity) suffice.  If 
lack of clarity regarding medical operability results, further testing is warranted (stair climbing, 
6 minute walk test, cardiopulmonary exercise testing).  The same parameters accepted as 
defining risk for anatomic pulmonary resection of primary lung cancer apply to pulmonary 
metastasectomy.  Figure 1.  
 
Recurrent disease/repeat PM  
Patients by definition have metastatic disease from the beginning and factors to consider are 
the same with recurrent pulmonary metastases after resection.  These include duration of the 
DFI, overall prognosis, expected benefit of medical treatment and the patient’s symptoms. With 
subsequent recurrences, DFI tends to shorten, symptoms worse and value of medical treatment 
less.  Cure is highly unlikely in these situations and palliation with prolongation of survival are 
the hoped-for treatment goals.   
 
Surgical objectives  
An indisputable objective of PM is diagnosis when metastasis has not been previously 
pathologically confirmed.  If PM is considered therapeutic (cure or long term palliation), 
objectives include complete resection (R0), pulmonary parenchymal sparing, defining extent of 
disease (lymphadenectomy) and, rarely, relief of symptoms.  Inability to achieve the primary 
goal of R0 resection precludes PM as therapy.  Figure 2. 
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Safety: surgical morbidity & mortality  
PM is safe.  Accumulated reports totaling 6122 patients [6, 30-32] demonstrate less-than-
lobectomy (wedge resections, segmentectomy) is the most common resection technique, used 
in 4,644 patients (75%).  Lobectomy, and seldom, pneumonectomy, was used in the remaining 
25%.  Perioperative safety is reflected in this preference for pulmonary parenchymal sparing.  
Operative mortality in these reports was 1.1% (71 patients) and morbidity, when reported [30-
32], was 11% (102 of 916 patients).  Average length of stay was 4.8-7.3 days. [30, 31] 
 
Technical aspects of surgical PM 
 
Extent of resection  
The necessity of achieving an R0 resection determines the extent of resection.  Less-than-
lobectomy is the dominant technique, allowing pulmonary parenchymal sparing.  Lobectomy is 
occasionally indicated.  Pneumonectomy is rarely appropriate and questionable as a technique 
in this patient population.   
 
Surgical approach  
Historically, manual palpation has been touted as required to “find” all the metastases when 
multiple are present on radiographic studies.  However, modern day CT scanning has very high 
resolution and CT is likely able to identify most, if not all, lesions, at least lesions that would be 
palpable.  Localization of lesions can be difficult if they are small and multiple, and certainly 
manual palpation adds tactile feedback that is otherwise limited with thoracoscopic 
approaches.  Finger palpation through port-sites or utility incisions as well as indirect palpation 
of the lung using instruments, such as a ring forceps, can aid in finding lesions using minimally 
invasive thoracoscopic techniques, but close attention to the CT scan and the anatomy of the 
lung real-time is as valuable.  The literature describes multiple localization techniques including 
percutaneous coils, wire localization, agar injection, dyes, etc, but there is little data proving 
cost-effectiveness and likely this will remain an individual preference in the near future, and 
limited by the experience of the specialists applying different techniques.  DFS does not appear 
to be affected by approach at least for colorectal metastases. [33] 
 
When an open technique is needed, usually for multiple or difficult to locate lesions, a decision 
remains as to the best open approach.  Single lung ventilation with high oxygen concentrations 
should be avoided in patients who have been exposed to bleomycin (often the case with 
testicular cancer).  If bilateral metastases are present, a clamshell incision (bilateral 
sternothoracotomies) with short intermittent apneic periods while using an FiO2 of 40% or less 
should be considered to avoid the risk of pulmonary fibrosis.  Bilateral lesions can be 
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approached through staged thoracotomies, thoracoscopies or median sternotomy if all lesions 
can be completely resected from this incision.  A sternotomy is usually well tolerated and can 
avoid the need for longer periods of single lung ventilation requiring a high FiO2. 
 
Consensus Statements: 
3. In oncologically and medically appropriate patients, PM can be considered with a 
preference for minimally invasive surgery (MIS) due to shortened postoperative 
recovery and lessened impact on short term quality of life.   
 
Strongly Agree: 75%  Agree: 8%     Neutral: 17%     Disagree: 0%      Strongly Disagree: 0%     
4. If goals of R0 and pulmonary parenchymal sparing are not accomplishable via MIS but 
loan themselves to open approaches (thoracotomy/sternotomy/clam shell), open 
techniques are appropriate.   
 
Strongly Agree: 83%  Agree: 17%     Neutral: 0%     Disagree: 0%      Strongly Disagree: 0%     
5. Pneumonectomy to accomplish PM is discouraged except in carefully selected patients 
undergoing multidisciplinary management.  
Strongly Agree: 62%  Agree: 30%     Neutral: 8%     Disagree: 0%      Strongly Disagree: 0%     
6. Although absolute number of pulmonary metastases is not a direct contraindication to 
PM, candidate selection for PM is best suited to patients harboring ≤ 3 pulmonary 
metastases.   
 
Strongly Agree: 33%  Agree: 42%     Neutral: 8%     Disagree: 8%      Strongly Disagree: 8%     
Lymph node (LN) management (Lanuti) 
Patients harboring pulmonary metastases from an extrathoracic solid organ, intrathoracic LN 
involvement often portends a worse prognosis. [34, 35]  Historically, thoracic surgeons 
uncommonly perform mediastinal LN dissection in the setting of metastatic disease.  The IRLM 
included 5206 patients with varying pathology and reported metastasis to mediastinal or hilar 
LNs in 5% of patients (11% germ cell tumors, 8% melanomas, 6% epithelial tumors, and 2% 
sarcomas).  Mediastinal LN sampling was discretionary and only 4.6% of patients had LNs 
assessed. [6]  Since 1997, more surgical oncologists perform LN assessment during PM, but 
systematic mediastinal lymphadenectomy remains controversial.  During a 2008 survey of the 
European Society of Thoracic Surgeons, 55% indicated that they regularly sample mediastinal 
nodes at the time of metastasectomy, whereas 33% avoided nodal dissection. [36]  Although 
current evidence suggests intrathoracic LN status is an important predictive factor in PM, there 
are no randomized data answering whether mediastinal lymphadenectomy has a therapeutic 
effect.  
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The frequency with which pulmonary metastases can metastasize to regional LNs is unclear but 
appears to be influenced by tumor histology (higher in colorectal, breast and renal cell 
carcinoma and less in sarcoma and melanoma).  Autopsy series demonstrated 33% incidence of 
mediastinal LN metastases in patients with non-pulmonary carcinoma. [37]  The incidence of 
intrathoracic LN metastases at the time of PM for colorectal cancer is higher than other 
epithelial pathologies and ranges from 12-44%. [38, 39]  In these retrospective series, 
mediastinal LN metastases were a significant negative indicator for survival.  Hamaji and 
colleagues reported on 319 patients who underwent mediastinal LN assessment during PM for 
colon cancer where 5-year survival was 48% in the LN negative group and 21% in the LN 
positive group.  The location of intrathoracic LNs (hilar or mediastinal) did not influence survival. 
[39]  In a larger retrospective series of 883 patients undergoing PM for an array of pathologies, 
3-year survival for patients with LN metastases was 38% compared to 69% in LN negative 
disease. [35]  
 
As surgeons select appropriate patients for pulmonary metastasectomy, the presence of 
intrathoracic LN involvement with lung metastases gives reason to pause.  Published 
retrospective series across varying pathologies universally document worse survival in patients 
harboring intrathoracic LN metastases.  This has prompted a call for more thorough 
preoperative evaluation of patients.  In 2010, the European Society of Thoracic Surgeons 
argued for mediastinal LN sampling prior to metastasectomy, and suggested that best practice 
would be to exclude patients from PM with thoracic nodal disease. [40]  The counter argument 
is that LN assessment allows for stratification of patients across different treatment strategies.  
For example, those patients who undergo curative PM with LN negative disease may be better 
suited for an observation strategy, whereas those with LN positive disease might benefit from 
systemic treatment.  As more effective systemic therapies evolve, patients may evolve to 
consideration of interval PM of residual or oligo-resistant disease in the lungs. 
 
Does mediastinal lymphadenectomy improve survival?  
The therapeutic effect of routine LN dissection during PM remains poorly defined.  Published 
retrospective series reporting outcomes in patients undergoing systematic LN dissection during 
the time of PM have inadequate control groups.  Winter et al performed a matched pair 
analysis of 110 patients who underwent mediastinal LN dissection during PM for renal cell 
carcinoma compared to 111 patients with no LN assessment. [41]  Analysis showed a trend 
toward improved survival (p=0.068) in patients undergoing LN dissection.  It should be noted 
that patients who harbored intrathoracic LN metastases in this study had a significantly shorter 
median survival than patients without LN metastasis (19 vs. 102 months, p<0.001).   
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Who should undergo mediastinal LN dissection? 
In patients considered for PM, thoracic surgeons will often perform mediastinal LN dissection in 
the presence of suspicious LNs found on radiographic imaging.  Despite diagnostic quality CT 
chest and PET, LN metastases can be missed.  Seebacher et al. reported on 209 patients 
routinely evaluated with CT and PET prior to pulmonary resection and underwent regional 
lymphadenectomy (n=158) or LN sampling (n=112) during PM for varying histologies. [42]  The 
authors observed unexpected intrathoracic LN metastases in 17% of patients, particularly with 
breast and renal cell pathology.  In view of the prognostic significance of unexpected LN 
involvement, the authors recommended routine LN dissection for all patients undergoing PM.   
 
Conclusion 
Recurrent observations can guide practice.  Since the incidence of intrathoracic LN metastases 
occurs in up to 44% of pulmonary metastases patients [39,41] (where detection with CT chest 
or PET can be falsely negative) systematic LN dissection or sampling at the time of PM seems 
reasonable.  Even patients with only one single pulmonary metastasis can have involved 
intrathoracic LNs.  Further justification of LN assessment includes setting expectations with 
patients and establishing whether adjuvant therapy is imminent or whether an observation 
strategy can be employed in LN negative disease.   Establishing specific recommendations for 
the use of intrathoracic LN assessment across individual histologies (epithelial cancers, 
sarcomas, germ cell tumors, renal cell cancers, melanoma) is not warranted given the data 
paucity.     
 
Consensus statement: 
7. LN sampling / dissection concomitant with PM should be considered since pulmonary 
metastasis accompanied by mediastinal LN metastasis predict poor survival.  
Strongly Agree: 39%  Agree: 38%     Neutral: 23%     Disagree: 0%      Strongly Disagree: 0%     
Nonsurgical local treatment modalities for pulmonary  
 
Role of thermal ablation and SABR  
For this review, only studies with ≥20 patients, a minimum reported 3-year overall survival and 
studies with mixed pathology, colorectal or sarcoma metastases (representing the largest 
reports allowing results to be more easily compared to studies involving surgical resection) 
were included.   No randomized studies exist.   
 
Thermal ablation 
Thermal ablation techniques include radiofrequency ablation (RFA), microwave and 
cryotherapy.  There are a number of systems available for each modality.  No studies compare 
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the available systems.  Although, most centers are migrating towards using microwave for lung 
ablation, there are no studies comparing modalities.  Finally, concerning pulmonary metastases, 
all of the studies fulfilling the inclusion criteria utilized RFA.  
 
Smaller tumor size has been demonstrated to be important when using RFA. [43]  Studies using 
RFA for pulmonary metastases used variable inclusion criteria with some studies including 
tumors diameter up to 80 mm. [44]  Successful ablation of large tumors is unlikely, and 
inclusion will adversely affect results.  
 
The largest report of ablation for pulmonary metastases included 566 patients with 293 
colorectal patients and 51 with sarcoma metastases. [45]  The authors demonstrated that the 
primary disease location, DFI, size and number of metastases were associated with overall 
survival on both univariable and multivariable analysis.    Addressing specifically patients with 
colorectal metastases size (>2cm) and number of metastases (>3), both were significantly 
associated with poorer survival.   
 
A confounding issue of many studies of pulmonary metastases ablation is only medically 
inoperable or patients who had failed other treatment modalities were included.  Despite this, 
survival results (Table 2) are comparable to that after surgery.  A prospective open-label study 
from Australia reported on 148 non-resectable patients with colorectal metastases. [50]  
Median survival was 51 months and 5-year survival 45%.  
 
Studies of sarcoma generally included smaller numbers of patients. A report of 20 patients with 
metastases 2cm or less, 3-year survival was 85%. [52]  In the above large French study of 566 
patients, there were 51 sarcoma patients. [44]  Although this study included tumors up to 
70mm, 3-year survival for sarcoma patients was still acceptable at 58%. 
Stereotactic Ablative Body Radiation Therapy (SABR) 
The utility of SABR for medically inoperable lung cancer patients has been described. [53]  It is 
not surprising that investigators report the use of SABR for pulmonary metastases patients.  
Lesion size, location (central versus peripheral) and number of metastases are important 
considerations from a technical and safety standpoint.  However, all studies are small and none 
report long-term outcomes.   
 
A study by Nyuttens et al. reported 30 patients with 57 pulmonary metastases. [54]  Large 
peripheral tumors received 60Gy (3 fractions), small peripheral tumors 30 Gy (1 fraction) and 
central tumors 60 Gy (5 fractions), illustrating the challenges in delivering SABR to patients with 
multiple tumors.  At a median follow-up of 36 months, 4-year survival was 38%.  Treatment was 
well tolerated with 5 (16%) patients reporting acute grade 3 toxicity.   
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
Another study reported  95 patients with 134 metastases. [55]  Patients with up to 4 
metastases were included.  Median survival was 38 months.  Three year survival was 56.2%.  
There was no grade 4 or higher complications.  Univariate analysis demonstrated the number of 
metastases and use of prior chemotherapy impacted outcome.   
 
Navarria et al reported 76 consecutive patients of variable histology with 118 lung lesions. [56]  
Eligible patients had up to 5 tumors treated.  Dose prescription varied for central and peripheral 
tumors, as well as larger versus smaller tumors.  Although 80 % of patients presented with 
grade 1 pulmonary toxicity (mostly radiation fibrosis in <25% of the lung), there was no grade 2 
or higher pulmonary toxicity.  Survival at 3-years was 73%.  The same group also reported a 
study of 28 patients with 51 sarcoma metastases. [57]  There was no grade 3 or higher acute 
toxicity, and 5-year survival was 60.5%.  This compares well to the 5-year survival reported in 
Table 2, for ablation of sarcoma metastases.  
Regarding colorectal metastases we included two studies. Overall survival in one study was 39% 
at 5 years and 58% at 3-years in the second. [58, 59]   
Factors to Consider When Selecting Therapy 
The availability of thermal ablation and SABR provides additional tools for treating patients with 
pulmonary metastases.  Generally, patients treated in these studies included patients who 
failed prior therapies, considered non-surgical candidates or who refused surgery.   
 
In the absence of randomized comparisons with surgery (even for primary lung cancer) it is 
reasonable to reserve these therapies for such patients.  Additionally we suggest that ablation 
/SABR be considered an option for patients who present with ipsilateral metastases after prior 
metastasectomy.   The morbidity of re-operation is avoided, and it is likely that such patients 
are at risk for a 3rd recurrence. 
 
SABR has a potential to impact pulmonary function in the long-term, particularly if multiple 
areas in the lung are treated.  Additionally a larger number of thermal ablation studies provided 
follow-up beyond 2-years.  For this reason we favor ablation over SABR.   On the other hand, 
ablation has been shown to be less effective for larger tumors in lung cancer patients, with 
higher local failures. [43] Therefore, SABR would be preferable for tumors larger than 3cm 
(perhaps 2cm), when resection is not an option.  Figure 3.  
 
 
 
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Table 2: Survival after Thermal Ablation for Pulmonary Metastases 
 
Author 
Year (n) 
Number 
of 
patients 
Modali
ty 
Pathology Median 
Follow-up 
(months) 
Median  
OS 
(months) 
3-yr OS 5-yr OS Median 
Tumor size 
(range) mm 
Ferguson J  
201546  
157 RFA  Colorectal 28 33.3 44% 19.9% 38* 
De Baere T 
201545 
566 RFA Mixed 35.5 62 67.7% 
 
51.5% 15(4-70) 
Wang Y  
201547 
67 RFA Mixed 24 24 46.4% 14.3% Max 50 
Petre EN 
201348 
45 RFA Colorectal 18 46 50% NR Max 35 
Von 
Meyenfeldt 
201144 
45 RFA Mixed 22 55 69% NR 16(5-80) 
Chua TC  
201051 
148 RFA Colorectal 29 51 60% 45% Max 50 
Matsui Y  
201549 
84 RFA Colorectal 37.5 67 65% 51.6% 15(5-35) 
Palussière J 
201150 
29 RFA Sarcoma 50 NR 65.2% NR Max 40 
Koelblinger C 
201452 
22 RFA Sarcoma 20 51* 85% NR 7(5-20) 
* = mean, Max=maximum tumor diameter, NR=not recorded 
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Table 3: Survival after SABR for Pulmonary Metastases 
 
Author  
Year (n) 
Number 
of 
patients 
Pathology Median 
Follow-up 
(months) 
Median OS 
(months) 
3-year 
survival 
4-year 
survival 
5 year 
survival 
Nuyttens JJ 
201554 
30 Mixed 36 36 NR 38% NR 
Wang Z 
201555 
95 Mixed 17 38 56.2% NR NR 
Navarria P 
201557 
28 Sarcoma 21 27.8 NR NR 43.3 
Navarria P 
201456 
76 Mixed 18 20 73% NR NR 
Comito T 
201458 
40 Colorectal 24 NR 58% NR NR 
Aoki M 
201660 
66 Mixed 31.7 NR 76% NR NR 
Singh D 
201461 
34 Mixed 16.7 NR 23% NR NR 
Baschnagel AM 
201362 
32 Mixed 27.6 40 63% NR NR 
Fillipi A  
201559 
40 Colorectal 20 46 NR NR 39% 
NR=not recorded 
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Consensus statement: 
8. Thermal ablation or stereotactic ablative body radiotherapy (SABR) is reasonable 
therapy for patients with pulmonary oligometastases particularly for patients 
considered high-risk for resection or refuse resection.   
 
Strongly Agree: 58%  Agree: 25%     Neutral: 8%     Disagree: 8%      Strongly Disagree: 0%     
Lung perfusion for metastasis  
 
Isolated lung perfusion (ILP) is a surgical technique developed to deliver high-dose 
chemotherapy to the lung, minimizing systemic exposure selectively delivering agent 
though the pulmonary artery and selectively diverting venous effluent.  ILP has the 
theoretical advantage of delivering high dose drug treatment to the lung while limiting 
exposure of sensitive critical organs, thus avoiding severe complications.  Moreover, ILP 
minimizes the impact of active drug loss from renal metabolism of the drugs. [63]  The 
lung was identified as an ideal organ for isolated perfusion because of its symmetry, 
exclusive arterial supply from the pulmonary artery, venous drainage into two 
pulmonary veins, and tolerance for hyperthermic conditions without significantly 
impairing systemic function. [64-66]  Johnston began research into ILP in 1983, 
investigating the toxicity and pharmacokinetics of doxorubicin in addition to the effect 
of hyperthermia on lung function and uptake of doxorubicin during ILP. [67] 
 
There are two perfusion techniques—a single pass and a recirculating blood circuit.  The 
single pass removes the venous effluent after circulating the chemotherapeutic agent 
through the lung one time versus a recirculating blood circuit which collects the effluent 
and redelivers the drug to the lung.   Technical variations include antegrade vs 
retrograde perfusion, blood flow occlusion techniques, endovascular blood flow 
occlusion, delayed clamp release and selective endovascular pulmonary artery 
perfusion. [68]   
 
In 1995, Pass and colleagues conducted a phase I trial looking at the safety and 
feasibility of ILP with TNF-α and interferon-γ in 15 patients.  Three partial responses 
were seen within 8 weeks of ILP however new nodules or regrowth appeared 7-9 
months postoperatively.  In all patients the non-perfused side exhibited stable or 
worsening disease by 8 weeks postoperatively. [69]  In 1996, Ratto and colleagues 
performed cisplatin based  ILP in 6 patients with lung metastases from sarcoma. [70]  
The authors completed all procedures without complications intraoperatively and no 
intraoperative or postoperative deaths.  In 2 of 6 cases a “contusion syndrome” 
occurred—radiographic signs of interstitial and alveolar edema.  At 13 months, 4 of 6 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
patients were alive without evidence of disease recurrence.  One patient died of 
extrapulmonary metastases and one patient had distant disease relapse.  Chemotherapy 
toxicity occurred in none of the patients.  Additionally, they performed staged lung 
perfusion on two patients with bilateral disease and determined it was safe.  In a second 
human study performed by Schröder and colleagues, 4 patients with sarcoma lung 
metastases underwent ILP with high-dose cisplatin and hyperthermia. Two of these 
patients had bilateral disease.  Three patients were alive and disease free at 12 months.  
The fourth patient died from cerebral metastases without evidence of local disease 
recurrence. [71] 
 
Burt and colleagues conducted a phase I trial of ILP with doxorubicin for patients with 
unresectable sarcoma pulmonary metastases. [72]  Eight patients were enrolled, 7 
patients were treated with 40 mg/m2 or less and 1 patient received 80 mg/m2.  There 
were no perioperative deaths, 6 patients died of disease on follow up out to 28 months.  
Unfortunately, there were no partial or complete responses to treatment.  Only 1 
patient showed stabilization of the lesions in the perfused lung when compared to the 
contralateral lung.   
 
In 2004, Hendricks and colleagues conducted a phase I trial for ILP with melphalan.  
There were a total of 16 patients divided into 8 groups, all of whom had pulmonary 
metastases from melphalan sensitive tumors.  There were no operative or postoperative 
mortalities.  Two patients who received 60 mg melphalan at 37⁰C developed lung 
edema and x-ray findings resembling a chemical pneumonitis.  During long term follow 
up, 7 of 16 patients had recurrent disease; 4 of 7 had disease outside of the lung and 1 
of 7 was in the previously perfused lung. [73]   
 
Complications of ILP have been limited to the lungs with transient pneumonitis, 
pulmonary edema, and decreases in FEV1 and DLCO.  Significant systemic toxicity has 
largely been avoided with the exception of reported doxorubin cardiac toxicity. [68]   
Despite a handful of phase I clinical trials showing that ILP can be performed in humans, the 
results are mixed and poor long term survival in these patients is the most common outcome. 
Continued clinical development of ILP is controversial, considering the evolution of novel 
therapeutics such as biologic targeted therapies and immunotherapy.   
 
Consensus statement: 
9. Outside of clinical research, isolated lung perfusion is not warranted for management of 
pulmonary metastases. 
 
Strongly Agree: 75%  Agree: 17%     Neutral: 8%     Disagree: 0%      Strongly Disagree: 0%     
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Cancer type-specific management of pulmonary metastases  
 
Colorectal cancer  
A SEER database study observed approximately 5% of colorectal cancer at initial staging had 
lung metastasis.   Incidence of lung metastases was higher among rectal primaries (5.6%) versus 
colon cancer (3.7%). [74]  Other studies report a 5-15% incidence of lung metastases including 
metachronous disease. [75]  In total a small fraction of patients with colorectal cancer develop 
pulmonary metastases; however, given this malignancy is common, management of pulmonary 
metastases from colorectal cancer remains an important oncologic challenge.   
 
Traditionally, the goal of PM in colorectal cancer is to achieve cure in a patient population in 
which metastatic disease usually connotes incurable.  For example, Hou et al reported survival 
of colorectal cancer patients with lung metastasis managed with the inclusion of PM. [76]  
Whether by thoracoscopic surgery or open surgery, the overall survival curve reached a plateau 
with long-term follow-up.  5-year overall survival rate was 50% and 46% (P=0.251) by 
thoracoscopy or open surgery, respectively.  The 5-year DFS rate approximated 35-40% for both 
surgical groups.   
 
Clinical data and PM 
Patient selection is at the core of the literature addressing PM in colorectal cancer.  Centers 
performing PM commonly use resectability and medical operability as the initial basis for 
considering PM.  Characteristics predicting a lower risk for recurrent cancer and/or a longer 
lifespan promote consideration of metastasectomy.  Treasure et al in 2014, summarized the 
prior findings of the landmark IRLM. [77]  Within the IRLM, colorectal cancer was the most 
common pathology.  Lower survival was predicted by multiple metastases, CEA elevation and a 
shorter (or no interval i.e. synchronous metastases) DFI between primary resection and 
development of metastasis.   
 
A systematic review and meta-analysis of risk factors for survival after PM in colorectal cancer 
was published in 2013. [78]  Approximately 3,000 patients from 25 studies published since year 
2000 were analyzed.   Four factors were associated with poor survival: 
1. short disease-free interval between primary tumor resection and development of lung 
metastases (HR 1.59, 95 % confidence interval [CI] 1.27-1.98) 
2. multiple lung metastases (HR 2.04, 95 % CI 1.72-2.41) 
3. involvement of hilar and/or mediastinal LNs (HR 1.65, 95 % CI 1.35-2.02) 
4. elevated pre-operative carcinoembryonic antigen (CEA) (HR 1.91, 95 % CI 1.57-2.32).  
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Interestingly, as other subsequent surgical series reported, a history of resected liver 
metastases (HR 1.22, 95 % CI 0.91-1.64) did not achieve statistical significance as a poor 
predictor of survival.   It remains unclear how such predictive indicators should be integrated 
into decision-making regarding PM. 
 
Based primarily on retrospective reports of selected patients typically with oligometastatic lung 
disease, 5-year survival rates following PM ranged from 30% to 60%.  At least a few hundred 
studies of PM for colorectal cancer have been published, all with the failings discussed 
previously.  A 2010 summary of over 1300 PM patients from 11 publications, with 4 reports 
including patients managed with both liver and lung metastasectomy, stipulated inclusion 
criteria of publication after 1989, at least 40 patients and at least 20 months median follow-up. 
[79]  The mean age ranged from 59 to 63 years.  The majority of subjects within each series had 
a solitary lung metastasis (26-75%).  In addition to 5-year survival rates of 33-65% in this review, 
thirty-day operative mortality rates were very low (0-2.4%).  Long-term survival in this patient 
population reflects a combination of surgical resection and neo-adjunctive and/or adjunctive 
chemotherapy.  It is unclear whether surgery or selection bias determined the long-term 
survival. [77]   
 
Only a randomized clinical trial will definitively determine the value of PM for colorectal cancer.   
The PulMiCC study (NCT01106261), A Randomized Trial of PM in Colorectal Cancer, completed 
its feasibility phase with enrollment of 70 patients and in 2015 began the formal randomized 
phase III trial portion. [80]  The UK-based, multi-center study plans to recruit 300 patients with 
colorectal adenocarcinoma and lung oligometastases who undergo clinical evaluation and MDT 
case review to determine appropriateness of PM.  Candidates are offered study participation 
and randomized to PM or observation as part of their overall oncologic therapy.   Overall 
survival is the primary endpoint of the phase III trial with secondary endpoints to include lung 
function, patient-reported quality of life and health economic assessment.   
 
Perioperative systemic therapy 
Without guidance of RCT evidence, a common practice approach relies on extrapolation from 
the more general colorectal cancer literature.  Adjuvant chemotherapy provides a benefit in 
DFS and overall survival in resected stage III and likely high-risk stage II colon cancer.  Given the 
recurrence risk is even higher for resected stage IV colorectal cancer, many oncologists accept 
the use of chemotherapy in the setting of colorectal cancer PM using the same course of 
fluoropyrimidine or doublet fluoropyrimidine and oxaliplatin as used in resected stage III 
disease.   
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The use of perioperative adjunctive chemotherapy for resectable liver metastases in colorectal 
cancer has been shown in a large randomized clinical trial to be safe and to prolong DFS.   No 
impact on overall survival was observed with longer follow-up. [81, 82]  The EORTC 40983 study 
randomized 364 patients to liver metastasectomy only versus liver metastasectomy and 
perioperative chemotherapy with fluorouracil, folinic acid and oxaliplatin (FOLFOX4 regimen) 
with median follow up of 8.5 years. The initial publication in 2008, noted several versions of 
analysis but with all randomized patients analyzed, the absolute increase in rate of progression-
free survival at 3 years was 7.3% (from 28.1% [95·66% CI 21·3–35·5] to 35.4% [28·1–42·7]; HR 
0·79 [0·62–1·02]; p=0·058).  Follow-up reporting in 2013, described a median survival was 61.3 
months (95% CI 51.0-83.4) and 5-year survival of 51.2% (95% CI 43.6-58.3) in the perioperative 
chemotherapy group and median survival of 54.3 months (41.9-79.4) and 5-year survival of 
47.8% (40.3-55.0) in the surgery alone group.   
 
Current cancer management societal guidelines 
In the United States the National Comprehensive Cancer Network (NCCN) Guidelines form the 
basis for clinical practice standards particularly with more common cancers.  NCCN Guidelines 
for colon cancer recommend for patients with resectable lung metastases either in isolation or 
together with liver metastases to be considered for metastasectomy. [83]  The strength of 
recommendation is category 2A (“Based upon lower-level evidence, there is NCCN consensus 
that the intervention is appropriate.”).  No distinction is made regarding strength of 
recommendation in terms of synchronous or metachronous metastases.   
 
The European Society of Medical Onocology consensus guidelines for the management of 
patients with metastatic colorectal cancer were updated in 2016. [84]   
• For patients with oligometastatic disease, systemic therapy is the standard of care and 
should be considered as the initial part of every treatment strategy (exception: patients 
with single/few liver or lung lesions, see below).  
• The best local treatment should be selected from a “toolbox” of procedures according 
to disease localization, treatment goal (“the more curative the more surgery”/higher 
importance of local/complete control), treatment-related morbidity and patient- related 
factors such as comorbidity/ies and age [IV, B].  
(Level of evidence (IV out of I-V range):  Retrospective cohort studies of case-control studies. 
Grade of evidence (B of A-E range):  Strong or moderate evidence for efficacy but with a limited 
clinical benefit, generally recommended.) 
 
The UK National Institute for Health and Care Excellence (NICE) addressed the role of resection 
for metastatic colorectal cancer that gives deference to a MDT assessment, presumably to 
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enhance the likelihood of evidence-based medical decision-making.  In addition, systemic 
therapy is recommended as initial therapy. [85] 
 
Consensus statement: 
10. In colorectal cancer patients, PM can be considered within a MDT construct with systemic 
therapy before or after PM.  
 
Strongly Agree: 92%  Agree: 8%     Neutral: 0%     Disagree: 0%      Strongly Disagree: 0%    
 
Renal cell carcinoma  
About one third of patients with renal cell carcinoma present with synchronous metastatic 
disease. [85]  Surgical approach is typically thoracotomy but approach did not impact long-term 
survival in a series of 191 patients if R0 resection was accomplished. [87]  The extent of surgical 
resection varied from wedge to lobectomy.  Reported thirty-day perioperative mortality rates 
ranged from 0 – 2.1%. [15, 88, 89]  Surgery-specific survival is confounded by inclusion of 
adjuvant chemotherapy, immunotherapy or extra-thoracic metastasectomies in many series. 
[15, 88-92]  In reports over the past 15 years, median survival ranged from 21 – 44 months.  
Table 4 
Specific predictive factors examined include completeness of resection, DFI, number, size and 
pulmonary location of metastases, age, tumor grade and gender.  In Hofmann et al, there were 
no survivors at 5-years if resection was incomplete versus 39% at 5 years.  They reported 
number of metastases and a single metastasectomy 5-year survival was 54.7% versus 32% for 
2-6 metastases. [97]  In a Japanese single institution case series of 25 patients over ten years 
reported overall 3-year survival of 53% and 5-year 35.5% with a 34 month median survival. 
Interestingly, DFI, location and number of metastases as well as completeness of resection 
were not significant predictive indicators. [93]  Number of metastases was not important in 
multivariate analysis of 105 patients but nodal involvement was a negative predictive factor. 
[89]  A Italian single-institution review of 48 patients between 1973 and 2008, the median 
survival was similar at 39 months, the 3-year survival 60%, 5-year 47% and 10-year 18%. [94]  In 
a Mayo Clinic study reporting metastasectomy from multiple sites, completeness of resection 
was predictive: an incomplete PM negatively impacted 5-year survival with a significant 
decrease from 73.6% to 12.95% at five years. [92]  Similarly, the Cleveland Clinic in 2005 
reported complete resection improved 5-year survival from 8 to 42%. [15]  In two series of 105 
and 191 patients, completeness of resection was important for survival, as was size of the 
lesions. [87, 89]   
Age has been identified as positive predictive indicator.  A previous citation reported > 60 years 
old having 70% 5-year overall survival versus 37% if < 60. [96]  Similarly older patients did better 
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in a series of multiple organ metastases.  The 5-year DFS was 22%, lower than when compared 
to metastasectomies form other sites. [90]  Gender and tumor grade were not significant 
predictive factors in a 1985-1999 German series. [87]   
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Table 4: Survival after PM in Renal Cell Carcinoma   
Author (year) Number of 
patients 
Median 
survival 
(months) 
Overall Survival (%) 
3-year 5-year 10-year 
Kawashima A 
et al (2011)93 
25 33.9 53.3 35.5 NA 
Kanzaki R et 
al (2011)94 
48 39 60 47 18 
Assouad J et 
al (2007)95 
65 NA NA 34.4 NA 
Marulli G et 
al (2006)96 
59 NA 63 53 NA 
Murthy SC et 
al (2005)15 
92 44.4 49 31 NA 
Piltz S et al 
(2002)89 
105 NA 54 40 33 
Pfannschmidt 
J et al 
(2002)87 
191 21.4 NA 41.5 NA 
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Consensus statement:  
11.  In renal cell carcinoma patients, PM can be considered within a MDT construct.   
 
Strongly Agree: 92%  Agree: 8%     Neutral: 0%     Disagree: 0%      Strongly Disagree: 0%     
Malignant melanoma  
Metastatic disease after initial treatment of malignant melanoma is found in approximately 
30% of patients.  Historically, median survival only reached 6-8 months with an estimated 5-
year survival < 5%. [98]  The incidence of pulmonary metastases in patients diagnosed with 
melanoma ranges between 30-40%.  The most common first visceral metastatic site for 
melanoma in large series is lung. [98]  In an analysis of 1,158 patients harboring melanoma 
metastases in visceral sites, those with only lung metastases had improved survival compared 
to other visceral sites. [100]  Systemic therapy remains the mainstay for treatment in stage IV 
disease but conventional chemotherapy and interleukin 2 have been toxic and disappointing.  
Historical data published in 1998 from the IRLM suggested PM for advanced stage melanoma 
had the worst outcome compared to germ cell tumors, epithelial tumors, and sarcoma. [6]  The 
probability of melanoma relapse in this surgical series (n=328) was 64%, where 73% of relapses 
involved extrathoracic organs.  Despite historical reports of poor prognosis for advanced 
melanoma, immune check-point inhibitors have greatly impacted survival since 2011 where 
subgroups of patients can achieve 60% 2-year survival. [101]  In an contemporary analysis of 
441 patients with stage IV melanoma from 2011-2014, the best overall survival was observed in 
patients treated with metastasectomy as primary treatment with R0 intent. [102]   
 
Favorable outcomes resulting from surgical resection of distant melanoma metastases in 
selected patients have been demonstrated in surgical series dating back to the 1990’s. [16, 103, 
104]  Several studies investigated the role of PM in advanced melanoma reporting 5-year 
survival rates of ~ 40% in highly selected patients with median follow-up of 18-55 months. [106, 
106]  Independent prognostic variables for improved overall survival in these series included: 
tumor doubling time > 60 days, tumor size < 2cm, number of lung metastases (≤1), complete 
resection and the absence of extrapulmonary disease.  Patients with multiple pulmonary 
metastases (>5) and no extrapulmonary disease were still able to achieve a 19% 5-year survival. 
[105]  In 1720 patients with pulmonary metastases from melanoma, PM was performed on 318 
patients.  The greatest benefit of metastasectomy in the surgically treated patients was 
observed in patients who presented with a DFI of > 5 years and harbored no extrathoracic 
disease.  Complete resection was accomplished in 249 (78%) of these patients. [107]    
In addition to the tenants of   (1) primary site control, (2) no extrathoracic sites of disease, (3) 
“long” DFI, and (4) “limited” number of pulmonary metastases, within a paradigm of systemic 
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immunotherapy for metastatic melanoma, anecdotally incomplete response of residual 
pulmonary metastases has been considered for PM.  
 
Consensus statement: 
12.  In malignant melanoma patients, PM can be considered within a MDT construct.   
 
Strongly Agree: 75%  Agree: 25%     Neutral: 0%     Disagree: 0%      Strongly Disagree: 0%     
Sarcoma  
Approximately 20%-40% of sarcoma patients develop pulmonary metastases with disease 
progression, often with lung as the only site. [108-114]  Because chemotherapy historically has 
limited response in sarcoma patients, PM is an accepted, even preferred, treatment for patients 
with lung lesions.  Never the less, as with other pathologies, sarcoma PM is not common.  
Nationwide data from Iceland described 81 patients treated for sarcoma over a 24-year period, 
only 5 of whom (6.5%) underwent PM. [3]   
 
Commonly reported data may identify several predictive indicators of increased survival, 
including: (1) metachronous versus synchronous, (2) DFI >12 months, (3) younger age, (4) 
limited number of metastases, (5) low pathologic grade, and (6) complete resection. [115-117]  
There is no agreed-upon number of lesions at which resection is thought to be futile, but it is 
likely more difficult to achieve complete resection or reach disease-free status with more 
lesions.  Furthermore, timing of resection remains controversial. [118]  Molecular markers as 
prognostic indicators has been reported, but is not widely adopted. [119]   
 
Despite aggressive resection strategies, sarcoma patients with pulmonary metastases 5-year 
survival is only 30% - 50%. [3, 5, 108, 111, 115, 116, 121]  Many patients experience pulmonary 
recurrence, although there are reports of “benefit” from a second PM. [111, 122]   
There appears to be a small survival difference for different sarcomas, with gynecological 
sarcomas showing better survival than osteosarcomas, which in turn have slightly improved 
survival compared with other sarcomas. [123-125]   
 
Combined treatment, that is, resection plus another local therapy (e.g. SABR), has been 
reported, and represents a trend in treating all metastases while reducing resection of 
pulmonary tissue. [126]  ILP with high-dose chemotherapy at the time of resection has also 
been reported, with modest benefit. [127]   
 
Consensus statement: 
13.  In sarcoma patients, PM can be considered within a MDT construct.   
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Strongly Agree: 92%  Agree: 8% Neutral: 0% Disagree: 0% Strongly Disagree: 0%     
Head & neck cancers  
Even though the metastasis rate from head and neck squamous cell carcinoma (HNSCC) is low 
and depends on loco-regional control and LN status, the lungs account for up to 70-85% of 
HNSCC metastases. [128]  Differentiating a primary lung squamous cell carcinoma (LSCC) from 
lung metastasis in a patient with HNSCC is challenging with the use of standard histopathology 
techniques.  Both LSCC and HNSCC have features in common, including histology, epithelial cells 
of origin and association with tobacco.  Although attempts have been made to distinguish 
metastases from primary lung cancer using genomics including loss of heterozygosity, [129] and 
microRNA profiling, [130] there is no gold standard to validate therapeutic approaches and 
potentially introduces selection bias in addressing the role of PM. [131-134] 
 
There are approximately twenty retrospective reports over the past twenty years in which 
authors reviewed single institutional experience with PM alone. There are only two reports 
retrospectively comparing chemotherapy versus PM. [135, 136] 
Positive predictive factors for PM alone include DFI, gender, age, site of origin of primary head 
and neck cancer and completeness of resection.  In 1992 Finley et al reported no five-year 
survivors in 18 patients treated surgically if their DFI was < 1 year but concluded that resection 
of solitary metastases resulted in long-term survival. [137]  Similar conclusions were reported 
by Wedman et al in describing 138 patients with pulmonary metastases from HNSCC, 21 of 
whom underwent PM. [138] There was a 59% 5-year survival in those undergoing lung 
resection compared with 4% for those who did not, concluding that a long but undefined DFI 
may select long term survivors.  A DFI < 12 months was noted to be a negative prognostic factor 
in several small series, [133, 137, 139] while other studies state 24-26 months as the significant 
DFI resulting in more favorable outcome. [131, 134, 140, 141]  Male gender has been found to 
be unfavorable. [131, 139]   
Histologic origin of the metastases is important. HNSCC versus glandular tumors was a poor 
prognostic factor in a small series. [139]  In a larger study comparing PM for HNSCC versus 
glandular origin head and neck tumors, the overall 5-year survival rate for the glandular tumors 
was 64% versus 34%. [140]  However, the SCC patients had potentially confounding worse 
predictive factors such as non-R0 resection, shorter DFI (< two years) and older age.  Similarly in 
two larger series completeness of resection translated into improved outcome [131, 135] but 
presence of nodal metastases was unfavorable. [131]  The fact that metastases from SCC origin 
do worse than those from glandular may reflect sampling bias and difficulty in distinguishing 
them from primary LSCC which are potentially under-treated with suboptimal resection.   
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As mentioned above, resection versus chemotherapy with matched pair analysis concluded PM 
resulted in significantly better survival.  PM lead to median survival was 19 versus 5 months 
[135] and overall 3-year survival of 68% versus 15%. [136]   
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Table 5: Survival after PM in Head & Neck Cancer    
Author (year) Number of 
patients 
Median 
survival 
(months) 
Overall Survival (%) 
3-year 5-year 
Yotsukura et 
al (2015)134 
34 77 NA NA 
Miyazaki et 
al (2013)136 
24 NA 68 NA 
Haro et al 
(2010)132 
21 NA 53.3 NA 
Daiko et al 
(2010)141 
33 21 43 NA 
Winter et al 
(2008)135 
67 19.4 NA 20.9 
Shiono et al 
(2009)131 
114 26 NA 26.5 
Chen et al 
(2008)139 
20 NA NA 59.4 
Nibu et al 
(1997)142 
32 NA NA 32 
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Consensus statement: 
14. PM in management of primary head & neck cancer can be considered in the context of DFI 
>12 months, ability to completely resection and absence of LN metastases.   
 
Strongly Agree: 42%  Agree: 42%     Neutral: 8%     Disagree: 8%      Strongly Disagree: 0%     
Nonseminomatous germ cell tumors (NSGCT)  
The lung is the most common site of visceral metastases from hematogenous dissemination.  In 
contrast to other solid neoplasms however, metastatic involvement of either the lung or 
mediastinum represents American Joint Committee on Cancer Stage III disease. [143]  The 
paradigm of platin-based chemotherapy followed by surgery to remove residual disease for the 
treatment of NSGCT is considered one of the most successful models of multimodality cancer 
therapy.  Recommendations for postchemotherapy PM are based on multiple factors including 
the serologic and radiographic response to chemotherapy, the presence or absence of 
teratomatous pathology in the orchiectomy specimen, and if performed prior to any thoracic 
surgical procedure, the pathologic findings of postchemotherapy retroperitoneal LN dissection 
(RPLND) as there is a high correlation between RPLND and lung pathology. [144, 145]  
Significantly elevated serum tumor markers (STM), alpha-fetoprotein (AFP) and beta human 
chorionic gonadotropin (HCG), after chemotherapy have a high sensitivity for persistent NSGCT. 
[146]  In the vast majority, STM normalize after first-line chemotherapy typically signifying 
resolution of the malignant nonseminomatous components with residual “benign” disease. 
Patients who demonstrate serologic progression of disease with persistent STM elevation after 
first-line chemotherapy are typically given second-line platin-based chemotherapy, including 
consideration of high-dose chemotherapy with autologous stem cell transplant. [147]    
 
Many patients with Stage III disease will completely resolve or have only minor residual lung 
abnormalities (<10 mm) after cisplatin-based chemotherapy.  Observation is then warranted.  It 
is estimated approximately 10-20% of all testicular NSGCT patients will have residual pulmonary 
disease following chemotherapy or subsequently manifest pulmonary disease during follow-up 
and warrant consideration of PM. [148, 149]  In approximately one half of these cases, there is 
residual mediastinal disease, which also requires removal, and needs to be part of surgical 
planning.  Unfortunately no accurate models exist for distinguishing complete tumor 
necrosis from remaining pathology for post-chemotherapy pulmonary abnormalities.  In 
addition to testicular/RPNLD pathology containing teratoma and normalized STM, CT 
findings suggestive of pulmonary teratoma include a rounded and/or cystic appearance.  While 
considered “benign”, teratoma has local growth potential as well as malignant transformation, 
therefore surgery is recommended with high cure rates. [150-152]  Moreover parenchymal 
sparing techniques involving “shelling out” of teratoma, is efficacious, avoiding large pulmonary 
resections. [148]  If PM in one lung is pathologically complete tumor necrosis, abnormalities 
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in the contralateral lung are observed, as there is a 90% pathologic concordance between 
lungs. [153]  Less commonly, malignant residual disease in the form of persistent NSGCT or 
malignant transformation of teratoma into non-germ cell cancer is present and may be 
anticipated by either elevated STM and/or testicular/RPNLD pathology.  In these cases, PM is 
undertaken in select patients to remove a limited number of areas, as cure is possible but 
significantly lower as compared to PM for teratoma. [151, 154-156]  In contrast to teratoma, 
which has low metabolic activity, PET imaging can be helpful to determine resectability in 
patients suspected of residual malignant disease.  Standard wide local excision (wedge) is 
utilized.  Adequate surgical margin less commonly requires anatomic pulmonary resection.   
 
PM following platin-based chemotherapy in the treatment of NSGCT of testicular origin has 
high curative potential with five-year survival rates ranging from 59% to 94%.  Although 
prospective randomized studies are lacking, high cure rates after PM generate a strong bias 
towards surgery.  Prognostic factors include International Germ Cell Cancer Cooperative Group  
risk (low, intermediate, high) at time of presentation and histology of resected disease after 
chemotherapy (benign - necrosis/teratoma; malignant - persistent NSGCT/malignant 
transformation into non-germ cell cancer).   
 
Consensus statements: 
 
15. When managing nonseminomatous germ cell tumors, PM is indicated for all residual lung 
abnormalities > 10 mm after platin-based chemotherapy with normalized STM suspected of 
containing teratoma.   
 
Strongly Agree: 67%  Agree: 25%     Neutral: 8%     Disagree: 0%      Strongly Disagree: 0%     
16. When managing nonseminomatous germ cell tumors, contralateral lung abnormalities can 
be observed if histology of unilateral PM demonstrates complete tumor necrosis.   
 
Strongly Agree: 46%  Agree: 46%     Neutral: 8%     Disagree: 0%      Strongly Disagree: 0%     
17. When managing nonseminomatous germ cell tumors, PM is indicated for select patients 
with limited number of lung abnormalities after first or second-line platin-based 
chemotherapy suspected of containing viable nonseminomatous cancer and/or malignant 
transformation of teratoma into non-germ cell cancer.   
 
Strongly Agree: 67%  Agree: 33%     Neutral: 0%     Disagree: 0%      Strongly Disagree: 0%     
 
Breast cancer  
The incidence of pulmonary metastases in patients diagnosed with breast cancer ranges 
between 7-24%. [157]  The initial purpose of performing metastasectomy in most breast cancer 
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patients is to confirm the diagnosis, establish hormone receptor status, and to rule out other 
primary or metastatic cancers.  Therapeutic PM in management of metastatic breast cancer is 
controversial.  Breast cancer metastatic to lung is regarded as a systemic disease with no clear 
role for therapeutic PM.  Despite this accepted practice pattern, several retrospective studies 
suggested a potential survival advantage in highly selected breast cancer patients undergoing 
PM for isolated or limited disease. [6, 158-164]  In a meta-analysis of 16 studies evaluating 1937 
patients undergoing breast cancer PM, a 46% 5-year survival was reported. [165]  Poor 
predictive factors were DFI < 3 years, incomplete resection, > 1 metastasis and negative 
hormone receptor status.  In contrast, a 16% 5-year survival was reported in a case series of 
breast cancer patients with metastases limited to the lungs and treated with chemotherapy 
alone. [165]  Similar to metastatic disease from other solid organs, PM of multiple or bilateral 
breast cancer metastases was associated with poor outcome. [167]  This concept is emphasized 
by a report of 81 patients with metastatic breast cancer with improved overall survival (103 vs. 
37 months) in patients harboring a single vs. multiple sites of disease. [20]  The extent of 
pulmonary resection and approach does not appear to influence survival.  [20, 167] 
 
Since many publications investigating the management of stage IV breast cancer with 
pulmonary metastases included patients on systemic therapy (hormonal, cytotoxic or targeted), 
the true contribution of PM to long-term survival is unclear. Staren et al examined medically 
treated patients with or without PM and found a significant survival improvement with the 
addition of PM (34 vs. 58 months).  Five-year survival in the medically treated group compared 
to the surgical group was 11% vs. 36%, respectively. [162]  Chemotherapy before or after PM 
did not influence overall survival in a cohort of 467 PM breast cancer patients. [158]  
 
There is evidence suggesting employing PM in breast cancer patients harboring hormone 
receptor-positive (either ER or Her2-neu) disease appears to have a survival advantage over 
receptor negative disease (77% vs. 12%, 5-yr survival, respectively). [160]  The presence of 
mediastinal LN metastases with breast cancer lung metastases portends a worse prognosis. [20, 
168]  However, a recent review concluded that, in view of the present relatively good survival 
among patients with metastatic breast cancer, the added value of PM is unclear. [169]    
 
Consensus statement:  
18. In breast cancer patients, PM can be considered within a MDT construct.   
 
Strongly Agree: 58%  Agree: 33%     Neutral: 8%     Disagree: 0%      Strongly Disagree: 0%     
Conclusion 
Best practice for PM in cancer management remains uncertain.  As with other areas of oncology 
care, physicians must hold themselves to evidence-based clinical standards, as best as possible, 
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and avoid the trap of doing something because it can be done.  The art of medicine is alive and 
well in many aspects of oncology care.  Ideally, continual review of current oncologic literature, 
familiarity with national/ societal guidelines, multidisciplinary and shared-decision making 
approach to patient care provides a framework for clinical care recommendations, even with a 
pure evidence-based approach is not possible.    
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Figure legends 
Figure 1 Evaluation for PM 
Figure 2 Surgical Techniques for PM 
Figure 3 PM Local Therapeutic Possibilities 
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